

*Correction*

Table III that appeared in the article "Varenicline for Smoking Cessation: A Review of the Literature," by K. Kaur et al (*Curr Ther Res Clin Exp.* 2009;70:35–54), contained errors. The correct table appears below:

**Table III. Results of varenicline clinical trials.**

Trial	Primary End Point (CAR weeks 9–12)	Secondary End Points	
		CAR weeks 9–24	CAR weeks 9–52
Jorenby et al <sup>4</sup>	Varenicline 43.9%	Varenicline 29.7%	Varenicline 23.0%
	Bupropion SR 29.8%	Bupropion SR 20.2%	Bupropion SR 14.6%
	Placebo 17.6%	Placebo 13.2%	Placebo 10.3%
Gonzales et al <sup>36</sup>	Varenicline 44.0%	Varenicline 29.5%	Varenicline 21.9%
	Bupropion SR 29.5%	Bupropion SR 20.7%	Bupropion SR 16.1%
	Placebo 17.7%	Placebo 10.5%	Placebo 8.4%
Tonstad et al <sup>37*</sup>	Varenicline 49.6%		Varenicline 43.6%
	Placebo 36.9%		Placebo 36.9%
Tsai et al <sup>38</sup>	Varenicline 59.5%	Varenicline 46.8%	
	Placebo 32.3%	Placebo 21.8%	
Aubin et al <sup>40</sup>	Varenicline 55.9%	Varenicline 32.4%	Varenicline 26.1%
	NRT 43.2%	NRT 27.3%	NRT 20.3%

CAR = continuous abstinence rate; SR = sustained release; NRT = nicotine replacement therapy.

\*Primary end point = CAR weeks 13–24; secondary end point = CAR weeks 13–52.